30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets
The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary...
Posts Tagged ‘NASDAQ:OREX’
7 Over-the-Counter Diet Pills that Work Without Exercise
Before we get to the list of 7 over-the-counter diet pills that work without exercise, we should ask ourselves if there exists such a thing. The short...
7 Most Popular Diet Pills That Work Fast Without Exercise
Are you interested in knowing the 7 Most Popular Diet Pills That Work Fast Without Exercise? I mean what better way to lose weight than to simply pop...
10 Best Performing Weight Loss Companies And Their Programs
The 10 best performing weight loss companies have found success in an increasingly competitive environment, one which is pitting supplement providers,...
Should You Avoid Orexigen Therapeutics, Inc. (OREX)?
The worries about the election and the ongoing uncertainty about the path of interest-rate increases have been keeping investors on the sidelines. Of...
Most Popular Healthcare Penny Stocks Among Hedge Funds
Although a great movie, The Wolf of Wall Street left many people thinking penny stocks are somewhat ‘untouchable’. Now, it is true that the...
Five Penny Stocks To Buy Based on Smart Money Sentiment
No doubt, penny stocks are for investors with a greater than average risk appetite, but considering their inexpensiveness and the possibility of towering...
What Do Hedge Funds Think of Orexigen Therapeutics, Inc. (OREX)?
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show...
These Five Biotech Stocks Ranked Among This UK-based Fund’s Favorites
Cheyne Capital is one of the few non-U.S firms that we track in our database. Managed by its founders, Jonathan Lourie and Stuart Fiertz, Cheyne employs...
Orexigen Therapeutics Inc. (OREX) and Spectranetics Corp (SPNC): Billionaires Klarman and Cohen Snapped Up These Healthcare Stocks
Seth Klarman’s Baupost Group has initiated a new passive stake in Orexigen Therapeutics Inc. (NASDAQ:OREX), a new filing the U.S. Securities and Exchange...
5 Healthcare Stocks Under $10 Ready To Pop
Investing in the healthcare sector can be tricky, especially if you’re looking for high returns and want to invest in clinical-stage companies,...
You Should Follow Hedge Funds Into One Semiconductor and One Healthcare Stock
In the first hours of trading, the markets showed slight signs of improvement, impacted by positive jobless claims data. In this way, the Dow Jones Industrial...
Foresite Capital Betting It All On These Four Healthcare Stocks
Jim Tananbaum’s Foresite Capital has filed its latest 13F with the Securities and Exchange Commission for the reporting period of March 31, disclosing...
Five Hedge Fund Moves in Healthcare Sector From This Week
The healthcare sector is usually very attractive to investors, since the companies involved in it have a great potential to grow. According to Morningstar...
Partner Fund Management Ups Stake in Orexigen Therapeutics, Inc. (OREX)
Christopher Medlock James‘, San Francisco-based, hedge fund Partner Fund Management has raised its position in Orexigen Therapeutics, Inc. (NASDAQ...
Arena Pharmaceuticals, Inc. (ARNA): Are Investors Worried?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued a press release pointing out that its marketing partner Eisai had started direct-to-consumer advertising...
Here is What Hedge Funds Think About Dynavax Technologies Corporation (DVAX)
What’s a smart Dynavax Technologies Corporation (NASDAQ:DVAX) investor to do? If you were to ask many market players, hedge funds are seen as useless...
Arena Pharmaceuticals, Inc. (ARNA), Orexigen Therapeutics, Inc. (OREX): VIVUS, Inc. (VVUS) Gets 3 CEOs in Less Than Two Months
Three different CEOs in a month and a half. Not exactly a ringing endorsement for VIVUS, Inc. (NASDAQ:VVUS) accelerating sales of its obesity drug Qsymia...
Should You Avoid Orexigen Therapeutics, Inc. (OREX)?
Should smart Orexigen Therapeutics, Inc. (NASDAQ:OREX) keep in mind the following data? In the financial world, there are a multitude of metrics shareholders...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Third Obesity Drug Moves Closer to FDA Approval
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘s Belviq, VIVUS, Inc. (NASDAQ:VVUS)‘s Qsymia, and Orexigen Therapeutics, Inc. (NASDAQ:OREX)&#...
Hedge Funds Aren’t Crazy About Amarin Corporation plc (ADR) (AMRN) Anymore
Is Amarin Corporation plc (ADR) (NASDAQ:AMRN) a buy? In the financial world, there are many metrics shareholders can use to track their holdings. A duo...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), Orexigen Therapeutics, Inc. (OREX): Who Will Be the Winner in the Fight Against Obesity?
The obesity segment of the health care industry is turning into a battleground. VIVUS, Inc. (NASDAQ:VVUS) entered the market first with its drug, Qsymia...
MannKind Corporation (MNKD), Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS) – Attention Biotech Investors: Stop Looking at Share Price
How do you track the value of companies you’re invested in? If you’re like most people, you probably check the increase or decrease in share...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Can the Newly Discovered Obesity Genes Help You Lose Weight?
Overweight? You can now officially blame it on your parents. Or at least the genes they passed along to you. Quite a few research papers published recently...
Arena Pharmaceuticals, Inc. (ARNA): Nothing to See Here, No Huge Sales Yet
Eisai and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) logged $4.1 million in net sales of their obesity drug Belviq in the second quarter. I will leave...
Will Arena Pharmaceuticals, Inc. (ARNA) Earnings Finally Explode Higher?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its quarterly report on Thursday, and it looks like the company might finally get itself into the...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): How You Should Play These Weight-Loss Drug Companies
The two weight-loss drug approvals in 2012 were the first in more than a decade. The excitement surrounding Arena Pharmaceuticals, Inc. (NASDAQ:ARNA...
VIVUS, Inc. (VVUS), AstraZeneca plc (ADR) (AZN): Great Job, Now You’re Fired
“As a founding CEO, over the past 22 years, Leland has secured four drug approvals, an unheard-of achievement for a small pharmaceutical company...
VIVUS, Inc. (VVUS) Extends Olive Branch, Follows With Fist
Oh, what a difference a day makes. On Saturday, VIVUS, Inc. (NASDAQ:VVUS) extended an olive branch to its largest shareholder and proxy-fight-adversary...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): One Weight-Loss Drug That Investors Forgot
You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient...
VIVUS, Inc. (VVUS): Obesity Drug Finally Hits Pharmacies
After gaining Food and Drug Administration approval nearly a year ago, patients can finally walk into a pharmacy and get their prescription for VIVUS,...
VIVUS, Inc. (VVUS): Qsymia Just Won The Lotto
After almost a decade, the FDA has once again started approving obesity drugs. VIVUS, Inc. (NASDAQ:VVUS)’s Qysmia and Arena Pharmaceuticals, Inc. (...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Weight Loss Drug Sweepstakes
The weight-loss industry has been heating up quite a bit over the past few quarters. First investors were reminded of the struggle between VIVUS, Inc. (...
Arena Pharmaceuticals, Inc. (ARNA) News: Positive Rating, Anti-Obesity Drug, Post-Launch Presentation & More
Editor’s Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Orexigen Therapeutics, Inc. (NASDAQ:OREX),...
Abbott Laboratories (ABT), VIVUS, Inc. (VVUS) – It’s Official: Obesity Is a Disease
According to the American Medical Association, obesity is now officially a disease. A highly preventable disease, but a disease nonetheless. I think that...
MannKind Corporation (MNKD), Orexigen Therapeutics, Inc. (OREX): Two Biotech Approval Outcomes That Might Affect You
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-...
Hedge Funds Are Crazy About Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation (NASDAQ:DVAX) has experienced an increase in hedge fund interest recently. To the average investor, there are dozens...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): New Obesity Drug Hits the Market
After a long wait, patients now have a choice between two new obesity drugs. They couldn’t be more different. Arena Pharmaceuticals, Inc. (NASDAQ...
Orexigen Therapeutics, Inc. (OREX): Are Hedge Funds Right About This Stock?
Orexigen Therapeutics, Inc. (NASDAQ:OREX) investors should pay attention to an increase in activity from the world’s largest hedge funds in recent...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): This Obesity Drugmaker Is Badly In Need of a Marketing Partner
As recently as a decade ago, the biggest hurdle for biotech companies wasn’t competition from their peers or even the sale price of their drugs....
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) Are NOT The Newest Obesity Drug Player
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had better check their rearview mirror because Novo Nordisk A/S (ADR) (NYSE:...
Amarin Corporation plc (ADR) (AMRN): What’s The Smart Money Think?
Amarin Corporation plc (ADR) (NASDAQ:AMRN) was in 19 hedge funds’ portfolio at the end of March. AMRN shareholders have witnessed a decrease in...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Why This Obesity Drug Is the Sector’s Best Bet
Editor’s Note: The original article incorrectly stated Schedule IV drugs are the second-most-restrictive. This version has been corrected and Motley...
Arena Pharmaceuticals, Inc. (ARNA): Why This Obesity Drug Is the Sector’s Best Bet
The obesity drug space is becoming increasingly complex and hard to predict. After months of waiting patiently, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA...
Orexigen Therapeutics, Inc. (OREX), And Three Pipeline Obesity Treatments You Should Watch
Obesity is a growing pandemic for many industrialized nations, especially in the U.S., where it now affects almost 36% of adults and 17% of adolescents...
Whole Foods Market (WFM), Chipotle Mexican Grill, Inc. (CMG): The 9 Most Obese Countries in the World
The world is expanding, but unfortunately it’s not the global economy whose waistline needs to go up a size. The rate of worldwide obesity has been...
Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS) & Orexigen Therapeutics, Inc. (OREX): What’s Weight Loss For Now?
It wasn’t that long ago that obesity drugs were considered a lifestyle drug. Doctors, the Food and Drug Administration, and insurers believed losing...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): A Belviq Battle
Things are beginning to look slightly up for obesity drugmaker VIVUS, Inc. (NASDAQ:VVUS) — mere weeks before a competing drug from Arena Pharmaceuticals...
Arena Pharmaceuticals, Inc. (ARNA): You Need To See These 5 Points
A sharp drop in Arena Pharmaceuticals (NASDAQ:ARNA) followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Orexigen Therapeutics, Inc. (OREX): The Bottom Line
VIVUS, Inc. (NASDAQ:VVUS)’ Qsymia has not received the unconditional consumer love that investors were hoping. The initial sales data has been...
